DDInter1420 DDInter927
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Pentamidine {u} (Compound) resembles {v} (Compound) Ospemifene
Pentamidine {u} (Compound) binds {v} (Gene) S100B
Pentamidine {u} (Compound) upregulates {v} (Gene) CDK7
Pentamidine {u} (Compound) downregulates {v} (Gene) TYMS
Pentamidine {u} (Compound) causes {v} (Side Effect) Azotaemia
Pentamidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Galantamine
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pentamidine {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Pentamidine (Compound) resembles Ospemifene (Compound)
Pentamidine (Compound) binds S100B (Gene)
Pentamidine (Compound) upregulates CDK7 (Gene)
Pentamidine (Compound) downregulates TYMS (Gene)
Pentamidine (Compound) causes Azotaemia (Side Effect)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Galantamine
Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene